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Abstract
Background: Validation of microarrays data by quantitative real-time PCR (qPCR) is often limited by the low
amount of available RNA. This raised the possibility to perform validation experiments on the amplified amino allyl
labeled RNA (AA-aRNA) leftover from microarrays. To test this possibility, we used an ongoing study of our
laboratory aiming at identifying new biomarkers of graft rejection by the transcriptomic analysis of blood cells from
brain-dead organ donors.
Results: qPCR for ACTB performed on AA-aRNA from 15 donors provided Cq values 8 cycles higher than when
original RNA was used (P < 0.001), suggesting a strong inhibition of qPCR performed on AA-aRNA. When
expression levels of 5 other genes were measured in AA-aRNA generated from a universal reference RNA, qPCR
sensitivity and efficiency were decreased. This prevented the quantification of one low-abundant gene, which was
readily quantified in un-amplified and un-labeled RNA. To overcome this limitation, we modified the reverse
transcription (RT) protocol that generates cDNA from AA-aRNA as follows: addition of a denaturation step and
2-min incubation at room temperature to improve random primers annealing, a transcription initiation step to
improve RT, and a final treatment with RNase H to degrade remaining RNA. Tested on universal reference
AA-aRNA, these modifications provided a gain of 3.4 Cq (average from 5 genes, P < 0.001) and an increase of qPCR
efficiency (from -1.96 to -2.88; P = 0.02). They also allowed for the detection of a low-abundant gene that was
previously undetectable. Tested on AA-aRNA from 15 brain-dead organ donors, RT optimization provided a gain of
2.7 cycles (average from 7 genes, P = 0.004). Finally, qPCR results significantly correlated with microarrays.
Conclusion: We present here an optimized RT protocol for validation of microarrays by qPCR from AA-aRNA. This
is particularly valuable in experiments where limited amount of RNA is available.
Background
Gene expression profiling using microarrays has rapidly
become an analytical tool of choice for translational
research laboratories. Genome-wide or more dedicated
microarrays are generally used as a fishing expedition to
identify candidate genes or pathways that can be used
either for their prognostic performance and/or for their
therapeutic potential in many diseases. The technique
relies on the relative quantification of mRNA expression
in cells or tissues. Circulating blood cells can be used as
an alternative to tissue biopsies when these are not
available. This alternative nevertheless assumes that a sys-
temic biosignature of the pathological state exists and can
be assessed through gene expression profiling of blood
cells. Consistently, while biosignatures of blood cells were
originally reported to be a useful prognostic tool for acute
myeloid leukemia [1,2], several studies later showed that
these biosignatures can also aid in the development of bio-
markers of several diseases affecting vital organs such as
the brain [3] and the coronary arteries [4]. Both peripheral
blood mononuclear cells [3,4] and whole blood cells [5]
have been used in such profiling experiments. One has
nonetheless to keep in mind that the method of RNA col-
lection, either from blood cells using the PAXgene™ tech-
nology for instance [6], or from buffy coats [3,4], is a
critical variable when designing research protocols using
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any medium, provided the original work is properly cited.microarray studies [5]. The PAXgene™ system is attractive
because it stabilizes RNA immediately after collection
without the need of rapidly isolating the leukocyte com-
partment. This is particularly relevant when designing
clinical protocols in which patients are included any time
of the day (patients with acute myocardial infarction for
instance). In addition, this system requires only a very lim-
ited volume of blood. However, the reliability of this sys-
tem to consistently detect all gene transcripts may be
questioned [7].
In addition to the type of blood collection, every steps
of the microarray technique can influence the quality of
the results. When minute starting amounts of RNA are
available, additional steps of amplification have to be
performed [8,9]. This scenario is frequent when using
the PAXgene™ system since RNA is extracted from only
2 . 5m Lo fb l o o d .S u c hR N Ai sg e n e r a l l yp r o c e s s e d
through a multiple steps procedure to generate ampli-
fied amino allyl RNA (AA-aRNA) coupled with fluores-
cent dyes. First, RNA is reverse transcribed, then
amplified with incorporation of amino allyl UTP (AA-
UTP) to serve as an arm to facilitate dye binding, and
finally coupled with fluorescent dyes before hybridiza-
tion onto microarrays. This fastidious protocol intro-
duces supplementary bias in the microarray technique,
sometimes leading to false positive discovery and erro-
neous results [10-13]. Some alternatives have been
developed, such as the Universal Linkage System tech-
nology (Kreatech Diagnostics, Amsterdam, The Nether-
lands) or the Ovation® technology (NuGEN, San Carlos,
CA, USA). Optimization of the amplification procedure
has been tackled by previous investigators, such as Wad-
dell et al. who reported two different methods for ampli-
fication of bacterial RNA to be assessed in microarray
experiments [14]. A popular approach to balance the
problem of false discovery is to validate microarray data
using an independent technique, such as Northern blot
hybridization, RNase protection assay or real-time quan-
titative PCR (qPCR), the latter being the more widely
used [15]. Most commonly performed on cDNA
obtained from reverse transcription (RT) of total RNA,
qPCR may also be performed on AA-aRNA leftover
from microarray experiments [Ambion Tips from the
Bench, Using Excess Labeled aRNA for Microarray Vali-
dation, TechNotes Volume 14(1)]. This is particularly
valuable when limited amount of RNA is available for
validation - in case of research protocols using the PAX-
gene™ system for instance. However, care should be
t a k e nw h e nd e s i g n i n gs u c hvalidation experiments.
Here, we report our experience with microarray valida-
tion by qPCR on AA-aRNA and we present an opti-
mized protocol that improves the reliability of this
validation.
Results and Discussion
An alternative to total RNA to perform microarrays
validation by qPCR
We took profit of an ongoing protocol of our lab which
aimed at identifying new prognostic biomarkers of renal
graft rejection. Hypothesizing that inflammation in the
organ donnor conditions the success of transplantation
[16], we analyzed the transcriptome of whole blood cells
of brain-dead organ donors by microarrays. The hypoth-
esis beyond this protocol was that graft rejection by the
receiver may be predicted by the transcriptomic analysis
of blood cells from the donor. Total RNA of whole blood
cells collected in PAXgene™ tubes from 22 brain-dead
organ donors was extracted. Since a limited volume of
blood (2.5 mL) was withdrawn in these tubes, only a low
amount of RNA could be extracted. After taking out 1 μg
of total RNA for microarrays, only 15 donors had enough
remaining total RNA to perform validation experiments
by qPCR. In an attempt to find an alternative material
than total RNA to perform validation experiments, we
tested whether qPCR could be performed on AA-aRNA
leftover from microarray experiments.
Amplification and amino allyl labeling of RNA
inhibits qPCR
To compare the effectiveness of qPCR from total RNA
and AA-aRNA, we used samples from the 15 donors for
which we had both AA-aRNA and remaining total
RNA. 1 μg RNA and 100 ng AA-aRNA were reverse
transcribed and resulting cDNAs were diluted 10-fold
before amplification by qPCR using primers specific for
the ACTB gene. The rationale for using different
amounts of RNA and AA-aRNA is that AA-aRNA is
generated from only mRNA (a T7-Oligo(dT) primer
being used during first strand DNA synthesis in the
amplification protocol) whereas RNA includes all RNA
species. The choice of 1 μg RNA and 100 ng AA-aRNA,
as already used by others [17], was performed to repre-
sent the low proportion of mRNA in total RNA. We
found that ACTB expression, as determined by Cq
values, was lower when using AA-aRNA compared to
RNA (Figure 1A). As a reminder, expression levels are
inversely correlated to Cq value, which corresponds to
the cycle of the qPCR for which a sufficient number of
amplicons have accumulated to allow for a reliable
quantification. Compiled from the 15 patients, Cq was
16.4 ± 1.0 (min-max 14.7-16.6) for RNA and 24.3 ± 2.0
(min-max 21.3-29.7) for AA-aRNA. This difference was
highly significant (t = -25.2; P < 0.001). As shown in
Figure 1B, there was a strong linear correlation between
t h eC qv a l u e so b t a i n e df r o mR N Aa n dA A - a R N Af o r
each patient (R
2 = 0.85; P = 0.00006). These results
attest that amplification and amino allyl labeling
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most probably due to steric inderance engendered by
incorporation of amino allyl arms. Therefore, the use of
AA-aRNA to validate microarray results by qPCR is an
attractive opportunity that requires optimization.
Amplification and amino allyl labeling decrease qPCR
sensitivity and efficiency
Following experiments were performed with a universal
reference RNA - the same as used for microarrays -
because of its high quality and availability. This RNA is a
commercially available mix of total RNA from 10 human
cell lines. We first aimed to reproduce the inhibition of
qPCR on AA-aRNA reported in Figure 1 with other
genes than ACTB. Universal reference RNA was either
amplified using T7 polymerase and coupled with amino
allyl arms to generate AA-aRNA, or kept under its pri-
mary form (RNA). Both RNA and AA-aRNA were
reverse transcribed with SuperScript II. Resulting cDNAs
were diluted 10-fold and subjected to qPCR using primer
pairs specific for 5 genes selected among our “genes of
interest”: vascular endothelial growth factor B (VEGFB),
matrix metalloproteinase 9 (MMP9), transferrin receptor
(TFRC), hepcidin antimicrobial peptide (HAMP), and
glyceraldehyde-3-phosphate dehydrogenase (GAPDH).
For instance, the rational for choosing VEGFB, a member
of the family of angiogenic factors, came from the con-
cept that angiogenesis plays a role in renal graft rejection
[18]. Figure 2A displays VEGFB amplification chart for
the two types of RNA. While this chart attested for the
reliability of the amplification, we observed that Cq
values increased from 20.1 for RNA to 27.7 for AA-aRNA
(Figure 2A and Table 1). Similar results were obtained
with the other genes (Table 1). Compiled from the 5
genes, Cq values were in average 5 cycles higher for
AA-aRNA compared with RNA (P = 0.02). Interestingly,
MMP9, which was readily detected when RNA was used
as input (Cq = 27.3), could not be detected with
AA-aRNA (Table 1). Then the two types of cDNAs were
serially diluted before amplification by qPCR to evaluate
qPCR efficiency. Analysis of VEGFB qPCR revealed that
qPCR efficiency decreased from 97.3% for RNA to 79.1%
for AA-aRNA (Figure 2B). Correlation coefficients of
standard curves were typically > 0.98. These data show
that amplification by T7 polymerase and incorporation of
amino allyl arms inhibit both PCR sensitivity and effi-
ciency. This inhibition may prevent the accurate quantifi-
cation of low-abundant genes such as MMP9.
Optimized protocol for reverse transcription (RT)
In an attempt to circumvent the loss of sensitivity of
qPCR performed with AA-aRNA, we modified the RT
protocol (Figure 3). We introduced a denaturation step
(5 min at 65°C) followed by a rapid cool-down on ice
and a 2-min incubation at 25°C to improve random hex-
amers annealing. After addition of reverse transcriptase,
a transcription initiation step of 10 min at 25°C was per-
formed to improve RT. This step is especially important
when the RT is primed by random primers. Upon RT
completion (50 min at 42°C) and enzyme denaturation
Figure 1 Amplification and amino allyl labeling inhibit qPCR.
Total RNA extracted from whole blood cells of 15 healthy brain-
dead organ donors was subjected to amplification by T7
polymerase and amino allyl labeling to generate AA-aRNA. 1 μgo f
un-amplified and un-labeled RNA and 100 ng AA-aRNA (amplified
and amino allyl labeled RNA but not coupled with fluorescent dye)
were reverse transcribed using SuperScript II, resulting cDNAs were
diluted 10-fold and subjected to qPCR using primers specific for
ACTB. (A) Cq obtained from the 15 samples are represented in a
box plot. A statistically significant difference was detected between
RNA and AA-aRNA (t = -25.23; P < 0.001; paired t-test). (B) Cq
obtained with RNA and AA-aRNA for each of the 15 patients were
strongly correlated (R
2 = 0.85; P = 0.00006; Pearson product
moment correlation). Similar results were obtained in two
independent experiments.
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for 20 min at 37°C to digest remaining RNA.
Protocol optimization improves RT yield
To test RT protocol optimization, we used the universal
reference RNA either under its native form (RNA) or
after amplification and amino allyl incorporation
(AA-aRNA). These 2 RNAs were reverse transcribed
either with the original RT protocol, the optimized RT
protocol without RNase H treatment, or the optimized
RT protocol with RNase H treatment. This dichotomy
allowed us to evaluate the effect of RNase H per se.
qPCR was performed on resulting cDNAs using primer
pairs recognizing the 5 genes VEGFB, MMP9, TFRC,
H A M Pa n dG A P D H .W h e nR N Aw a su s e da ss t a r t i n g
material, the optimized RT protocol decreased the mean
Cq value for the 5 genes by 1.2 cycle (from 22.0 ± 4.5
to 20.8 ± 4.3; P < 0.001) and RNase H treatment did
not induce a further decrease of Cq value (Figure 4A).
With AA-aRNA, the decrease of Cq value induced by
RT protocol optimization was stronger: 2.6 cycles were
gained (from 24. 8 ± 4.1 to 21.4 ± 4.2; P < 0.001).
Again, RNase H treatment did not further decrease Cq
values (Figure 4B). Interestingly, whereas MMP9 was
below the detection threshold of qPCR assay with
AA-aRNA and the original RT protocol (Cq > 35 cyles),
protocol optimization was able to make it detectable
(Figure 4B). The same experiment was repeated using
RNA extracted from blood cells of one brain-dead organ
donor and gave similar results: RT protocol modifica-
tions induced a gain of 1 cycle and 3.3 cycles when
RNA and AA-aRNA were used as inputs, respectively
(data not shown). These results show that optimization
Figure 2 Amplification and amino allyl labeling decrease qPCR
efficiency and sensitivity. One μg RNA and 100 ng AA-aRNA from
human universal reference were reverse transcribed with
SuperScript II. (A) Ten-fold dilutions of resulting cDNAs were
subjected to qPCR using primer pairs specific for VEGFB. The
amplification chart shows higher Cq values for AA-aRNA compared
with RNA. (B) cDNAs obtained from reverse transcription of RNA
and AA-aRNA were serially diluted and qPCR was performed to
evaluate qPCR efficiency using VEGFB-specific primers. qPCR
efficiency calculated from standard curves (E = [10
-1/slope]-1) is
down-regulated by amplification and amino allyl labeling.
Table 1 Cq values obtained by qPCR using RNA and
AA-aRNA
Gene RNA AA-aRNA
VEGFB 20.1 27.7
MMP9 27.3 ND
TFRC 18.4 24.6
HAMP 23.3 23.6
GAPDH 14.5 16.5
Mean ± SD 20.7 ± 4.9 25.6 ± 7.0*
qPCR was performed on universal reference RNA and AA-aRNA using primer
pairs specific for the indicated genes. ND: not detectable. *P = 0.02 vs RNA
(one way repeated measures ANOVA).
Figure 3 Scheme depicting RT protocol optimizations.
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available for qPCR when working either with RNA or
AA-aRNA, with a stronger effect with AA-aRNA.
RNase treatment improves qPCR efficiency
We next investigated whether the optimized protocol
and RNaseH treatment alter RT efficiency and linearity.
It was indeed reported that RNase H may allow for
amplifying certain genes which may not be accessible to
PCR [19]. For this purpose, different quantities of
AA-aRNA (100-1000 ng) were reverse transcribed using
either the original or the optimized RT protocol, with or
without RNase H treatment. Resulting cDNAs were
diluted 10-fold and subjected to qPCR to determine the
efficiency (E) and the linearity (R
2) of the qPCR. Figure
5A displays the results of the qPCR for VEGFB and
Figure 5B illustrates E and R
2 values obtained for the 5
genes tested with the different experimental protocols.
Intersection of dotted lines in graphs of Figure 5B
indicates the optimal values for E (-3.2) and R
2 (1). A
gathering of genes near this optimum reveals an
improvement of qPCR parameters. Table 2 gathers E
and R
2 values for the 5 genes, together with statistical
analyses. As shown in Figure 5, addition of RNase H to
the original protocol improved qPCR efficiency for the 5
genes tested. When E values from the 5 genes were
averaged, a significant improvement of E following
RNase H treatment was found: from -1.96 ± 1.10 to
-3.43 ± 0.30 (P = 0.003) when using cDNA generated by
the original protocol, and from -1.36 ± 0.70 to -2.88 ±
0.29 (P < 0.001) when using cDNA generated by the
optimized RT protocol (Table 2). E was not significantly
improved by the optimized protocol if RNase H treat-
ment was not performed (Table 2). Overall, RT protocol
optimization (with RNase H) improved qPCR efficiency
from -1.96 ± 1.10 to -2.88 ± 0.29 (P = 0.02). Linearity of
the qPCR was not statistically significantly affected by
the optimized protocol or RNase H (Table 2). However,
protocol optimization and RNase H treatment clearly
improved R
2 for selected genes such as VEGFB and
HAMP (Figure 5 and Table 2).
T h e s ed a t as h o wt h a tR N a s eHt r e a t m e n ti m p r o v e s
qPCR efficiency. This result is consistent with previous
data [20]. Considering that RNase H degrades RNA
paired to cDNA after RT, improvement of qPCR para-
meters by RNase H suggests that RNA/cDNA duplexes
may have prime amplification by Taq polymerase, indu-
cing the synthesis of other PCR products than those tar-
geted by the specific qPCR primers. However, the
observation that RNase H does not modify Cq values
(Figure 4) is consistent with a minor effect of RNA/
cDNA duplexes on qPCR outcome. Also, fusion curves
obtained for each qPCR consistently showed a single
peak, attesting for the specificity of the amplification
(not shown). Together with the previous observation
that RT protocol optimization improved RT yield and
qPCR sensitivity, these results demonstrate that our
optimized RT protocol with RNase H treatment pro-
vides an optimal cDNA from AA-aRNA to be used in
qPCR experiments.
Figure 4 Protocol optimization improves RT yield.O n eμgR N A
(A) and 100 ng AA-aRNA (B) obtained from universal reference RNA
were used as inputs to either the original RT protocol (black bars),
the optimized RT protocol without RNase H treatment (white bars),
or the modified RT protocol with RNase H treatment (hatched bars).
Resulting cDNAs were subjected to qPCR using primer pairs specific
for VEGFB, MMP9, TFRC, HAMP and GAPDH. Threshold Cq values for
each gene and the mean ± SD of the 5 genes are indicated. RT
protocol optimization decreased Cq values and RNase H did not
induce a further decrease. *P < 0.001 vs original RT protocol (one
way repeated measures ANOVA). ND: not detectable.
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Page 5 of 13Figure 5 RNaseH improves qPCR efficiency. Different quantities of AA-aRNA from universal reference RNA (100-1000 ng) were used as inputs
into either the original RT protocol or the optimized RT protocol, with or without RNase H treatment. Resulting cDNAs were diluted 10-fold and
subjected to qPCR using primer pairs specific for VEGFB, MMP9, TFRC, HAMP and GAPDH. Cq values were plotted against the Log of the
concentration of the AA-aRNA used for RT and linear regression was applied. qPCR efficiency (E) was calculated by the slope of the regression
line. A slope of -3.2 indicates optimal efficiency. qPCR linearity (R
2) corresponds to the correlation coefficient of the regression line. A coefficient
R
2 of 1 indicates optimal linearity. (A) Representative experiment using VEGFB primers. (B) Plots representing qPCR efficiency as a function of
linearity for the 5 genes tested. Optimum conditions are indicated at the intersection of dotted lines corresponding to E = -3.2 and R
2 = 1. E was
improved by RNase H treatment.
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qPCR primers
Random hexamers used in traditional RT protocol bind
anywhere in the RNA, allowing RT of all RNA indepen-
dently of their size. In contrast, the RT of the amplifica-
tion procedure that generates a AA-aRNA for
microarrays is performed with T7 oligo(dT) primers
that anneal only to the poly(A) tails of mRNA. This is
an important limitation of this protocol since only
mRNA below a certain length (typically around 1000
bp) may be correctly reverse transcribed, and therefore
detectable by qPCR. To address this issue, we designed
5 pairs of primers located at different distances from the
3′ end of the hif1a gene (Table 3). These primer pairs
had similar ratings as determined by the Beacon soft-
ware used for their design, ruling out the possibility that
the differences observed could originate from the pri-
mers themselves. HIF1A was chosen for these experi-
ments for the length of its coding sequence and the
possibility to design 5′ pairs of primers evenly distribu-
ted on this sequence. cDNAs generated from 1 μgR N A
and 100 ng AA-aRNA from universal reference were
diluted 10-fold and subjected to qPCR using HIF1A pri-
mers. As expected, a similar Cq value was obtained with
the 5 pairs of primers when using RNA for qPCR,
attesting that primer position does not affect Cq values
when RT is performed with random hexamers (Figure
6). In contrast, moving away primers from the 3′ end
highly increased Cq values when using cDNA generated
from AA-aRNA (Figure 6). These results highlight the
importance of designing primer pairs close to the 3′ end
o ft h eg e n ew h e nw o r k i n gw i t hA A - a R N A .W es u g g e s t
designing qPCR primers closer than 1000 bp away from
the 3′ end of the target gene when performing qPCR
from AA-aRNA.
Validation of microarray results by qPCR using AA-aRNA
As stated before, the ultimate goal of performing qPCR
on AA-aRNA is to validate microarray results. We
therefore tested whether the implementations described
in this paper improved this validation. For this purpose,
we used AA-aRNA obtained from blood cells of the
same 15 brain-dead organ donors described earlier. On
one hand, these 15 AA-aRNA were analyzed by gen-
ome-wide microarrays. Among the 25,000 genes repre-
sented on the microarrays, 5 genes were selected based
on their significant association with renal graft rejection
(analyses not shown here): the cytokine Tumor Necrosis
Factor-a (TNF-a), the accessory protein LY96, the neu-
trophil elastase ELANE, the adhesion molecule annexin
A1 (ANXA1), and the transcription factor Signal Trans-
ducer and Activator of Transcription 3 (STAT3).
Expression levels obtained by microarrays were calcu-
lated as the log ratio sample vs universal reference
RNA. On the other hand, expression levels of these
genes were assessed by qPCR starting with the same 15
AA-aRNA that were used for microarrays. 100 ng of
each AA-aRNA was reverse transcribed either with the
original RT protocol or with the optimized RT protocol.
The resulting two types of cDNA were subjected to
qPCR using primers specific for ACTB, GAPDH, LY96,
ELANE, ANXA1, STAT3 and TNF-a. Two pairs of pri-
mers were used for TNF-a,t h ef i r s to n e( T N F - a-1)
l o c a t e d1 2 4 3b pa w a yf r o mt h e3 ′ end of the tnf-a gene
and the second one (TNF-a- 2 )l o c a t e d1 1 9b pa w a y
from the 3′ end (Table 3). Figure 7 depicts Cq values
obtained by qPCR: for all genes, Cq values were lower
when using AA-aRNA reverse transcribed with the opti-
mized RT protocol compared with the original RT pro-
tocol. However, this effect failed to reach statistical
significance for LY96. On average, a gain of 2.7 cycles
Table 2 Effect of protocol optimization and RNase H on qPCR efficiency and linearity
VEGFB MMP9 TFRC HAMP GAPDH Mean ± SD P vs-RNase H P vs original protocol P vs original protocol/-RNase H
Efficiency
(slope)
Original protocol
- RNase H -1.50 NA -3.59 -1.15 -1.59 -1.96 ± 1.10
+ RNase H -3.74 NA -3.63 -3.13 -3.24 -3.43 ± 0.30 0.003
Optimized protocol
- RNase H -1.13 -1.24 -2.53 -1.26 -0.65 -1.36 ± 0.70 0.13
+ RNase H -3.28 -2.83 -3.04 -2.71 -2.54 -2.88 ± 0.29 <0.001 0.16 0.02
Linearity (R
2) Original protocol
- RNase H 0.66 NA 0.97 0.63 0.95 0.80 ± 0.18
+ RNase H 0.99 NA 0.98 0.99 0.97 0.98 ± 0.01 0.16
Optimized protocol
- RNase H 0.99 0.91 0.99 0.72 0.87 0.90 ± 0.11 0.38
+ RNase H 0.98 0.97 0.97 0.99 0.98 0.98 ± 0.01 0.19 0.64 0.16
This table gathers the results obtained from experiments shown in Figure 5 and shows statistical analyses. P values were determined using one-way repeated
measures ANOVA and paired t-test. NA: not applicable.
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Page 7 of 13was afforded by RT optimization (P = 0.004, Figure 7).
This gain appeared to be independent of the primers
position on the gene since some primers are located
close to the 3′end (GAPDH, LY96, ELANE, ANXA1,
TNF-a-2,) and others are located more distantly (ACTB,
STAT3, TNF-a-1). However, the primer position was
important in the case of TNF-a since the use of primers
d i s t a n tf r o mt h e3 ′ end (TNF-a-1) prevented the
detection of TNF-a in cDNA generated with the origi-
nal RT protocol whereas primers located closely to the
3′ end (TNF-a- 2 )a l l o w e df o rT N F - a detection (Figure
7). This result illustrate that designing qPCR primers
close to the 3′ end is critical for specific target genes. In
our search to identify new prognostic markers of graft
rejection, the possibility to validate microarray data for
TNF-a was important since TNF-a is a main pro-
inflammatory cytokine and inflammation influences
Table 3 List of primers used in this study
Gene cDNA length
(bp)
Genbank accession
number
Forward primer Reverse primer Distance from 3’ end
(bp)
ANXA1 1399 NM_000700 GGAACGCTTTGCTTTCTCTTG TTCTGGTGGTAAGGATGGTATTG 795
ACTB 1852 NM_001101 AGAAAATCTGGCACCACACC GGGGTGTTGAAGGTCTCAAA 1520
ELANE 938 NM_001972 CGGGCTAATCCACGGAATTG TTGTCCTCGGAGCGTTGG 273
GAPDH 1310 NM_002046 CAGCCTCAAGATCATCAGCA TGTGGTCATGAGTCCTTCCA 782
HAMP 430 NM_021175 AGTGGCTCTGTTTTCC GAAGTGGGTGTCTCG 292
HIF1A 4082 NM_001530 AGAAGGTATGTGGCATTTATTTGG CAGGGTAGGCAGAACATTTAGG 516
CGTGTTATCTGTCGCTTTGAGTC TTTCGCTTTCTCTGAGCATTCTG 1611
TTGGCAGCAACGACACAG GCAGGGTCAGCACTACTTC 2440
AGCCGAGGAAGAACTATGAAC ACTGAGGTTGGTTACTGTTGG 3149
CCTGACAAGCCACCTGAG TCGTGAGACTAGAGAGAAGC 3892
LY96 619 NM_015364 TGCCGAGGATCTGATGAC ATTAGGTTGGTGTAGGATGAC 245
MMP9 2387 NM_004994 AACTACGACACCGACGAC CAGGCGGAGTAGGATTGG 1587
STAT3 4900 NM_003150 GCTGGCTGACTGGAAGAG AGTTGAGATTCTGCTAATGACG 3943
TFRC 5241 NM_003234 ATTGAACCTGGACTATGAGAG GGAAGTAGCACGGAAGAAG 3140
TNF-a-1 1669 NM_000594 AGTGACAAGCCTGTAGCC GGACCTGGGAGTAGATGAG 1243
TNF-a-2 1669 NM_000594 AAACAATGCTGATTTGGTGAC GGCGATTACAGACACAACTCC 119
VEGFB 1172 NM_003377 CTGTGGTGGCTGCTG ACTGGCTGTGTTCTTCC 901
Primers were designed with the Beacon Designer software. All PCR products were sequenced to confirm specificity.
Figure 6 Choice of primer location for qPCR from AA-aRNA.
One μg of universal reference RNA and 100 ng AA-aRNA were
reverse transcribed using our optimized RT protocol. Resulting
cDNAs were diluted 10-fold and subjected to qPCR using 5 pairs of
primers located at different distances of the 3’ end of the hif1a
gene. Cq values were plotted against these distances. Linear
regression lines illustrate the effect of increasing the distance from
3’ end. Moving away primers from the 3’ end increased Cq values
when performing qPCR with cDNA generated from AA-aRNA.
Figure 7 RT protocol optimization decreases qPCR Cq values.
Total RNA extracted from blood cells of the same 15 brain-dead
organ donors used in Figure 1 was amplified and amino allyl
labeled to generate AA-aRNA. 100 ng of each of these AA-aRNA
were then reverse transcribed to cDNA using either the original or
the optimized RT protocol, and qPCR was applied to assess
expression levels of ACTB, GAPDH, LY96, ELANE, ANXA1, STAT3 and
TNF-a. Results are represented as Cq values for each gene (mean ±
SD of the 15 donors) and as the mean ± SD of the 7 genes. The
optimized RT protocol decreased Cq values. ND: not detectable. *P
< 0.001 and #P = 0.004 vs original RT protocol (paired t-test).
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Page 8 of 13graft rejection [16]. Additionally, quantification of low-
abundant genes is critical for biomarker studies since
biomarkers are often low-abundant proteins encoded by
weakly expressed mRNAs [21]. GAPDH was introduced
in these analyses to avoid a possible inhibitory effect
due to the location of ACTB primers (1520 bp away
from the 3′ end) and was chosen for normalization in
subsequent experiments.
We next determined whether the optimized RT proto-
col affected the correlation between microarray results
and qPCR data. For this purpose, expression levels
obtained by qPCR were normalized to GAPDH and
plotted against expression values obtained by microar-
rays (Figure 8). Linear regression was applied and corre-
lation coefficients R
2 and P values as determined by the
Pearson product moment correlation are gathered in
Table 4. RT protocol optimization did not alter the level
of correlation between microarrays and qPCR (Figure 8
and Table 4). Correlation coefficients were typically
above 68% and flanked with P values below 0.01,
Figure 8 Correlation between microarrays and qPCR. Gene expression profiles of blood cells from 15 brain-dead organ donors were
analyzed by microarrays covering 25,000-genes. Among these, the following were considered in these experiments: TNF-a, LY96, ELANE, ANXA1
and STAT3. Expression levels of these 5 genes obtained by microarrays were calculated as the log ratio sample vs universal reference RNA. 100
ng of AA-aRNA remaining from microarray experiments were reverse transcribed using either the original or the optimized RT protocol and
assessed for expression levels of these genes by qPCR. GAPDH was used as reference gene for normalization. For each gene, expression data
from microarrays (log ratio gene/reference) were plotted against expression data from qPCR calculated with the formula (2
Cq gene - Cq GAPDH).
Correlation between microarrays and qPCR, either using the original (●) or the optimized (○) RT protocol, were calculated by Pearson product
moment correlation and are summarized in Table 4. Linear regression lines are displayed for correlations between microarrays and qPCR data
obtained with the original (full lines) or the optimized (dotted lines) RT protocol. RT protocol optimization did not modify the correlation
between microarrays and qPCR.
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Page 9 of 13attesting for a significant correlation between microar-
rays and qPCR data (Table 4). The strongest correlation
was observed for ELANE (R
2 = 0.94) but this was due
to one outlier. Interestingly, the observation that both
qPCR and microarrays reported a high level of ELANE
expression for this outlier argues for the effectiveness of
qPCR to validate microarray data. This expression was
also particularly elevated when qPCR was performed
from un-amplified and un-labelled RNA (not shown).
With respect to TNF-a,w ef a i l e dt oc o r r e l a t eq P C R
data with microarrays, even with the optimized RT pro-
tocol and qPCR primers chosen close to the 3′ end of
the gene (Figure 8 and Table 4). This cannot be
explained by a low level of expression of TNF-a since
Cq values obtained by qPCR with TNF-a-2 primers
were around 24 cycles (Figure 7). Two transcripts can
be generated from the tnf-a gene, a large transcript
with 4 exons and a smaller transcript having only 2
exons. One could have explained the absence of correla-
tion between qPCR data and microarrays if the qPCR
primers would have detected a different transcript than
the oligonucleotide probe of the microarray. However,
both TNF-a-1 and TNF-a-2 primers, as well as the
microarray probe, recognize the large transcript. This
result illustrates the difficulty to validate microarrays
data by qPCR encountered for some genes, which may
consequently be considered as false positives. Of note,
TNF-a expression values obtained by microarrays did
not correlate with qPCR performed on un-amplified and
un-labelled RNA (not shown). Overall, the correlation
between microarrays and qPCR on AA-aRNA obtained
in our study is comparable to the correlations obtained
with RNA ([22,23] and unpublished data). Therefore,
qPCR data obtained from AA-aRNA are consistent with
microarrays and our optimized RT protocol did not
affect this correlation.
Conclusions
We have implemented an optimized protocol for the
validation of microarrays data by qPCR. This protocol
allows using AA-aRNA leftover from microarray experi-
ments when limited amount of RNA is available. It can
aid in the quantification of low-abundant genes and
provides a significant level of correlation between micro-
arrays and qPCR. In addition, this protocol provides
high-quality material that can be used to validate
expression of relevant genes that may be highlighted by
other approaches than microarrays. Such approaches,
some of them being increasingly used in the field of bio-
marker or therapeutic targets discovery, include bioin-
formatic analysis of functional networks or signaling
pathways [24,25].
Methods
RNA samples
Two types of RNA were used in this study. First, RNA
was extracted from whole blood cells of 22 brain-dead
organ donors. Median age was 50 (36-64), 14 donors
were males, and the initial events that led to brain death
were cerebrovascular accident (n = 10), brain trauma (n
= 6), acute onset of brain hypoxia (n = 2), suicide (n =
2) and trauma (n = 2). According to the French legisla-
tion, studies on brain-dead patients do not require
informed consent. The French “Agence de la Bioméde-
cine” approved the protocol and blood was withdrawn
after signature of next of kin for all scientific studies of
the brain-dead patient. Diagnosis of brain death was
established according to the criteria of the French
“Agence de la Biomédecine” [26]. Arterial blood (2.5 ml)
was withdrawn from the arterial catheter in PAXgene™
blood RNA tubes (PreAnalytix®, BD Europe, Erembode-
gem, Belgium), in the operation room, just before organ
harvesting. PAXgene™ tubes were stored at -20°C before
RNA extraction. Total blood RNA was isolated using
the PAXgene™ Blood RNA kit (Qiagen, Courtaboeuf,
France) according to the manufacturer’s instructions.
RNA quantity was assessed with a Nanodrop (Thermo
Scientific, Wilmington, USA) and quality was evaluated
using the Agilent 2100 Bioanalyzer (Agilent Technolo-
gies, Palo Alto, CA). All RNAs used in the present study
were of high quality and un-degraded (OD260/OD280 >
1.9 and OD260/OD230 > 1.7, RNA integrity number
(RIN) > 8). Second, we used the universal human refer-
ence RNA comprising total RNA from 10 human cell
lines (Stratagene Europe, Amsterdam, The Netherlands).
All nucleic acid samples were stored at -80°C until use.
Table 4 Correlation between microarrays and qPCR
STAT3 ANXA1 ELANE LY96 TNF-a-1 TNF-a-2
Microarrays vs original RT protocol R
2 0.72 0.84 0.94 0.68 NA -0.09
P 0.002 0.0001 0.0002 0.005 NA 0.77
Microarrays vs optimized RT protocol R
2 0.69 0.84 0.94 0.73 0.11 0.07
P 0.005 0.0001 0.0001 0.002 0.70 0.80
This table gathers correlation coefficients (R
2)a n dP values estimated by Pearson product moment correlation from experiments shown in Figure 8. See legend
to this figure for details. NA: not applicable.
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Page 10 of 13RNA amplification and amino allyl labeling
Messenger RNAs were amplified using the Amino Allyl
MessageAmp® kit (Ambion, Cambridgeshire, United King-
dom) according to the manufacturer’s protocol, starting
with one μg of total RNA. This protocol is based on the
Eberwine RNA amplification procedure [9]. Briefly, the
generation of multiple antisense RNA copies of each
mRNA is obtained by first strand cDNA synthesis with an
oligo(dT) primer tagged with a T7 promoter. After second
strand synthesis, an in vitro transcription reaction is per-
formed with T7 RNA polymerase in presence of 5-(3-ami-
noallyl)-UTP (AA-UTP). This produces amplified amino
allyl RNA (AA-aRNA) that can be coupled with fluores-
cent dyes for microarray experiments.
Reverse transcription of RNA and AA-aRNA
The same RT protocol was applied to RNA (un-amplified
and un-labeled RNA) and AA-aRNA (amplified and amino
allyl labeled RNA but not coupled with fluorescent dye). 1
μg of RNA and 100 ng of AA-aRNA were reverse tran-
scribed into cDNA using the SuperScript II reverse tran-
scriptase (Invitrogen, Merelbeke, Belgium) with the
following protocol: RNA or AA-aRNA was mixed with the
5× RT buffer, random hexamers, dNTPs and DTT in a total
volume of 19 μl. Samples were then heated to 42°C for 2
min, and 1 μL of SuperScript II was added to a total volume
of 20 μl. Final concentrations were: 50 mM Tris-HCl, 75
mM KCl, 3 mM MgCl2, 0.5 mM dNTPs, 10 mM DTT, 200
U of SuperScript II, 180 ng of random hexamers (Invitro-
gen). RT was allowed for 50 min at 42°C and was followed
by enzyme inactivation at 70°C for 15 min. The absence of
contaminating DNA was checked using no RT assays.
Optimized RT protocol. RNA or AA-aRNA were
mixed with 180 ng random hexamers and dNTPs to a
total volume of 13 μL, heated to 65°C for 5 min and
rapidly chilled on ice for 5 min. 4 μlo f5 ×R Tb u f f e r
and 2 μl DTT were then added and samples were incu-
bated for 2 min at 25°C. Then 1 μLo fS u p e r s c r i p tI I
was added and samples were pre-incubated for 10 min
at 25°C before RT for 50 min at 42°C. RT was stopped
by heating to 70°C for 15 min. Finally, 1 μL( 2U )o f
RNase H (Ambion) was added, and incubation was con-
tinued for 20 min at 37°C. Reagent concentrations were
the same as above.
Quantitative real-time PCR (qPCR)
cDNAs obtained from RT of RNA or AA-aRNA were
diluted 10-fold and 4 μL were mixed with 16 μLo f
SYBR®Green Master Mix (Biorad, Nazareth, Belgium)
containing 300 nM of each primer (final volume 20 μL).
Amplification was carried out in the IQ5 thermal cycler
(BioRad) under the following conditions: heating for 3
minutes at 95°C, 40 cycles of denaturation for 30 sec-
onds at 95°C, followed by an annealing/extension for 1
min. A negative control without cDNA template was
run in every assay and measures were performed in
duplicates. Primers were designed with the Beacon
Designer Pro 7.0 software (Premier Biosoft) and their
characteristics are indicated in Table 3. Primers specifi-
city was assessed using the NCBI BLAST tool http://
www.ncbi.nlm.nih.gov/BLAST/Blast.cgi. HPLC-purified
primers were obtained from TIB MOLBIOL (Berlin,
Germany). Expression levels were calculated using the
freely available GENEX Expression Macro (Biorad)
which takes into account primer efficiency. Melting
curves were analyzed and amplicons were sequenced to
confirm the specificity of the reaction. See ‘additional
file 1’ for MIQE checklist.
Microarrays
Transcriptomic profiles of whole blood cells from 22
brain-dead organ donors were obtained using oligonu-
cleotide microarrays representing 25,000 genes [27].
Total RNA extracted from whole blood cells was used
in combination with reference RNA (Universal Human
Reference RNA) to provide an internal standard for
comparisons of relative gene expression levels across
arrays. Messenger RNAs were amplified using the
Amino Allyl MessageAmp™ kit (Ambion®, Cambridge-
shire, United Kingdom) according to the manufac-
turer’s protocol, starting with one μgo ft o t a lR N A .
Five μg of each amino allyl aRNA were labeled with
Cy3 or Cy5 (Amersham, Buckinghamshire, United
Kingdom). Dye coupling to amino allyl aRNA was
measured using the ND-1000 spectrophotometer. Dye
coupling yield >5% was a prerequisite for further ana-
lysis. 750 ng of each amino allyl aRNA labeled Cy3 or
Cy5 (reference RNA or donor RNA) were combined
and hybridized on oligonucleotide microarrays repre-
senting 25,000 genes. Four microarrays per patient
were hybridized and a dye-swap was performed (2
microarrays patient-Cy3/reference-Cy5 and 2 microar-
rays patient-Cy5/reference-Cy3). Hybridization steps
were performed using the Agilent Technologies sys-
tem. Briefly, RNA was fragmented with a fragmenta-
tion buffer before mixing with a hybridization buffer.
Microarrays were blocked with 50 mM ethanolamine
in 50 mM borate buffer pH = 9.0. Agilent’sh y b r i d i z a -
tion chambers and rotating oven were used for hybri-
dization at 60°C for 17 h at 4 rpm. Microarrays were
washed for 10 min in 6X SSC, 0.005% Triton X-102,
f o r5m i ni n0 . 1 XS S C ,0 . 0 0 5 %T r i t o nX - 1 0 2 ,a n dw e r e
then dried by centrifugation before scanning using an
Axon 4000B microarray scanner and the GenePix Pro
6® software (Molecular Devices, Berks, UK). Self photo-
multiplicator gain adjustment and 0.1% saturated spots
were allowed during scanning. Spot finding and raw
data quantification of all four microarrays for each
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MAIA® freeware. A Lowess non linear normalization
step was performed with the Acuity® software (Molecu-
lar Devices) to compensate for uneven Cy3-Cy5 distri-
bution. The normalized log ratio Cy3/Cy5 was used in
subsequent steps. A filtering step was then performed
to remove genes that were not present in at least three
microarrays out of four. The quality and reproducibil-
ity of each of the four microarrays per patient were
evaluated using ANOVA, correlation coefficients and
Self Organizing Maps drawn with the Acuity® software.
Data are stored in the Web based Microarray Data
manager MEDIANTE and are available at the Gene
Expression Omnibus database (http://www.ncbi.nlm.
nih.gov/geo/) under the accession number GSE8723.
Before statistical analysis, genes not present in at least
50% of the patients were filtered out. Supervised analy-
sis was performed using the Significance Analysis of
Microarrays (SAM) software which correlates gene
expression with an external variable such as EF value.
Two class unpaired t-test and 100 permutations were
used. Gene missing values imputation was performed
via a K Nearest Neighbour algorithm normalization
using 10 neighbours.
Statistical analysis
Results are presented as mean ± SD or as median (inter-
quartile range) for description of demographic charac-
teristics. Comparisons between two groups were
performed with two-tailed t-test for Gaussian data and
Mann-Whitney test for non Gaussian data. Comparisons
between multiple groups were performed with one way
ANOVA for Gaussian data and Kruskal-Wallis one way
ANOVA on ranks for non Gaussian data. Paired data
a m o n gm u l t i p l eg r o u p sw e r ec o m p a r e dw i t ho n ew a y
repeated measures ANOVA and all pairwise multiple
comparison procedures (Holm-Sidak method). Correla-
tion tests were performed using the Pearson product
moment correlation method. Statistical significance tests
were generated with the SigmaPlot v11.0 software and
the SigmaStat software (for Windows version 3; SPPS
Inc. Chicago, Illinois, USA). A P value < 0.05 was con-
sidered statistically significant.
Additional material
Additional file 1: MIQE_checklist. Minimum information for publication
of quantitative real-time PCR experiments guidelines.
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